Dr. Sabine Hazan
speaker
74 appearances
1 recordings
1 series
first heard May 2025
last heard May 2025
Dr. Sabine Hazan’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Go back to the diet that's comfortable from your ancestors that you feel doesn't cause you any problems. The moment you start having bloating, gas, you know that doesn't agree with your gut. So pay attention to that.
Well, you could have probably bagel and lox too, right? Yes, he could. That's actually true. He could. No chives.
So what we're noticing is the loss of microbes that cause the allergies. It's the loss of microbes that possibly could. And I'm going to say possibly because, you know, in medicine, you can never say that causes, then everybody's going to shoot at me. But I think possibly celiac sprue is a loss of microbes. Allergies is loss of microbes. I think all of it really begins in the gut.
So I think because I'm doing, I've done clinical trials and I've done all these clinical trials for pharma on biologics. And actually I did the study on MAP, which was a quad therapy, quadruple therapy of antibiotics hitting really mycobacteria perituberculosis.
So what we discovered with Crohn's disease was that, or what I discovered, it's not published yet because it was a small study as I was doing the clinical trial. is that there possibly could be one third of people that have mycobacteria perituberculosis. One third of people have may have a genetic problem and one third of people may have a gut dysbiosis.
My own data actually showed that it was a loss of bifidobacteria in new. So if you if you look at all the new onset naive, non-treated Crohn's patients, you'll notice they have zero bifidobacteria. So when you go to that route and you fix early the loss of bifidobacteria, you may have a chance at restoring it.
One of the things that I noticed with bovine immunoglobulins, which is the blood of the cow that's spun around the clear stuff, is that it actually increases the bifidobacteria. So if we're lucky in the young people, Those people, if you catch them early and you give them bovine, you may resolve them. I have one case that I published was a young man who was started on Numera.
The mom didn't want him to be on Numera. We put him on bovine and right away he went into remission and I've not seen him in five years. And you could see his dysbiosis. Really? He had a lot of bacteroides, zero bifidobacteria. As we gave him the bovine, the bifidobacteria went up. The bacteroides went down. This kid has not seen me.
And in fact, the father, you know, who owned a coffee company talked about it on a show one day about that case. But we published that case. You know, the other thing that we're starting to see is really that correction of of of bifidobacteria can help these folks. Now, there's a population that you cannot get them that even if you change the diet, you change everything.
They need to be on biologics. And then there's a population that the biologics are not working. So, you know, there's no genetic component. And those are the people that fit very well with MAP. Because you have to like ask yourself, did those people have, you know, did they eat beef from a cow that had mycobacteria perituberculosis? So mycobacteria perituberculosis is very similar.
It causes in cows a disease called Yoni's disease, which is very similar to Crohn's disease. And you see these cows, they're wasted and they're having diarrhea. And basically, if you're unfortunate to have, you know, eaten the meat from that cow, then you may end up having that problem. So is a vaccine the answer? Maybe, but I tend to think that we really need to be more precise.
And I think that's what the microbiome is going to help us.
So bifidobacteria is the bacteria. But there is a genetic component to Crohn's disease, right? That's where the biologics are going after. One important thing about that clinical trial.
Right, exactly.
So you could test, you could join a clinical trial. We have a lot of clinical trials where you could join. We have one on Crohn's disease. We can test your kids and we can kind of tell you, look, we're seeing no bifidobacteria. And that could help your kids with that. The second thing you could do is you could do genetic testing, obviously, to see. But here's the thing.
The majority of people with Crohn's disease that we see in our offices do not necessarily transfer to their kids. That's a relief. And I'll tell you that clinical trial that I did, they came to me to enter a trial where they got quadruple therapy, right? What I realized after the fact was that one third responded and that's how it came on that, oh, well, maybe one third has MAP, right?
Because it's very difficult to isolate mycobacteria per tuberculosis. Right. And then what happened is the other one third went into having biologics and they were fine on biologics. And then one third ended up developing C. diff. And that's how we discovered because they were taking antibiotics. Right. And so they were on quadruple antibiotic for a long time.
So those patients is who we did fecal transplant on. And out of that population, you know, some resolved and some didn't resolve. So then you have to kind of look at why did some resolve? Did I use the right donor? It happened that, you know, one, if I recall, was taking a lot of nutraceuticals that were the equivalent of antibiotics. You know, there's so many nutraceuticals out there.
They're killing the gut. And so no matter how much I was giving him a new microbiome of his daughter, he was not resolving the problem. But another one I treated with a brother, and those are the two cases that come up in my mind, did great and resolved Crohn's disease. So that's how you kind of differentiate.
Absolutely true. I mean, there's so much corruption. Look, the company, the scientists and the investors and investors retracted my hypothesis, you know? So when in medicine does an investor of a product get to have any say in what paper gets to stay or gets retracted, right? Never. And when does a PhD scientist... go to the editor and say, we tracked this paper, we found all these problems.
Showing 41–60 of 74 · page 3 of 4
← Previous
Next →